A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium

Trial Profile

A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Pazopanib (Primary) ; Paclitaxel
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms PLUTO
  • Most Recent Events

    • 12 Apr 2017 Results published in the Journal of Clinical Oncology.
    • 10 Jan 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
    • 08 Nov 2014 Accrual to date is 93% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top